Andy Scharenberg

Andy Scharenberg is the Co-founder and CEO at Umoja Biopharma. Andy has over 20 years of experience in the biotech industry, having served as Chief Scientific Officer at Casebia Therapeutics, a Scientific Advisory Board member at bluebird bio, and Chief Scientific Officer at Cellectis therapeutics, where they implemented the TALEN gene editing technology into allogeneic CAR-T cell platform. Scharenberg has also served as a Professor of Pediatrics and Immunology at the University of Washington and as a Co-founder and Member of the Board of Directors at Pregenen.

Andy Scharenberg received their MD from the University of North Carolina School of Medicine and is currently practicing medicine.

Some direct reports include Ryan Crisman - Co-founder and CTO, Nushmia Khokhar - Chief Medical Officer, and Tim Gardner - EVP, Strategy and Business Development.